Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.

Item

http://www.wikidata.org/entity/Q44667229

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.

@en

Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.

@nl

type

Item

label

Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.

@en

Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.

@nl

prefLabel

Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.

@en

Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.

@nl

P1476

Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.

@en

P2093

Bjarne Anker Jensen

http://www.w3.org/2001/XMLSchema#string

Elisabeth Ralfkiaer

http://www.w3.org/2001/XMLSchema#string

Henrik Birgens

http://www.w3.org/2001/XMLSchema#string

Marianne Hamilton Therkildsen

http://www.w3.org/2001/XMLSchema#string

Nielsaage Tøffner Clausen

http://www.w3.org/2001/XMLSchema#string

Ole Weiss Bjerrum

http://www.w3.org/2001/XMLSchema#string

Per Boye Hansen

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Primary (essential) thrombocythemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis--a critical evaluation of clinical and histomorphological data.

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis.

Idiopathic myelofibrosis: a clinical study of 80 patients.

Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis.

Clinicopathological impact of the interaction between megakaryocytes and myeloid stroma in chronic myeloproliferative disorders: a concise update.

Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia.

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.

Thalidomide in agnogenic and secondary myelofibrosis.

P304

238-242

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.10431

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hans K. Hasselbalch

P577

2003-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8993662

http://www.w3.org/2001/XMLSchema#string

P698

14635203

http://www.w3.org/2001/XMLSchema#string